← FDA DRUG APPROVALS

FDA ANDA · ANDA078804

ASPIRIN AND DIPYRIDAMOLE

Sponsor: BARR

APPLICATION
ANDA078804
TYPE
ANDA
ORIGINAL APPROVAL
2009-08-14
LATEST ACTION
2022-08-05
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

ASPIRIN AND DIPYRIDAMOLEPrescription
ASPIRIN 25MG, DIPYRIDAMOLE 200MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2022-08-05Labeling · Supplement 10 · standardAP
2020-02-27Labeling · Supplement 7 · standardAP
2020-02-27Labeling · Supplement 6 · standardAP
2018-05-02Manufacturing (CMC) · Supplement 2 · unknownAP
2009-08-14OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →